Literature DB >> 16019657

The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London.

J D Johnston1.   

Abstract

Dr. Mary Walker discovered in 1934 that physostigmine and Prostigmin temporarily restored muscle function in patients with myasthenia gravis. In the next five years, Dr. Walker and colleagues provided clinical evidence for the weakness of myasthenia gravis being caused by a "disturbance of transmission of excitation from motor nerve to voluntary muscle presumably caused by a deficiency of acetylcholine. Physostigmine (or Prostigmin) compensated for the lack of acetylcholine by delaying its destruction." Dr. Walker and colleagues also described the association between familial periodic paralysis and hypokalaemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019657     DOI: 10.1080/096470490512580

Source DB:  PubMed          Journal:  J Hist Neurosci        ISSN: 0964-704X            Impact factor:   0.529


  3 in total

1.  Mary Broadfoot Walker (1888-1974).

Authors:  J D Johnston
Journal:  J Neurol       Date:  2007-09       Impact factor: 4.849

Review 2.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

Review 3.  Pathophysiological basis in the management of myasthenia gravis: a mini review.

Authors:  Aiswarya Binu; Sarath S Kumar; Uma Devi Padma; Krishnadas Madhu
Journal:  Inflammopharmacology       Date:  2022-01-21       Impact factor: 4.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.